^
Association details:
| Biomarker: | EGFR overexpression + KRAS mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | HTI-1511 (Microtubule inhibitor, EGFR-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
HTI-1511, a novel anti-EGFR-ADC, overcomes mutation resistance and demonstrates significant activity against multiple tumor types in preclinical studies
Excerpt:
Here we screened a panel of over 70 tumor cell lines derived from various solid tumor malignancies for both EGFR expression by flow cytometry and sensitivity to cell growth inhibition by HTI-1511 in vitro....A separate study in a NSCLC (KRASmut) PDX model demonstrated a dose dependent response with greater than 100% TGI at 1.0 and 3.0 mg/kg (both p<0.05, and also p<0.05 to a non-cognate antibody ADC control).…These results support further development of HTI-1511 as a possible treatment for EGFR overexpressing tumors, including those with downstream activating mutations in the KRAS/BRAF pathway.
DOI:
https://doi.org/10.1158/1538-7445.AM2017-50
